Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib plus pembrolizumab in anaplastic or poorly differentiated thyroid carcinoma
2017-004570-34Phase 2Completed
- Sponsor
- Universitätsklinikum Freiburg
- Start
- Jul 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenvatinib and pembrolizumab in anaplastic thyroid cancer (ATC) and poorly differentiated thyroid carcinoma (PDTC), sponsored by Universitätsklinikum Freiburg. Primary endpoint: Objective response rate. Started Jul 2018; status: completed.
02
Drugs
lenvatinibpembrolizumab
03
Conditions
anaplastic thyroid cancer (ATC)poorly differentiated thyroid carcinoma (PDTC)
Beyond the preview
Go deeper on 2017-004570-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004570-34.